Core Viewpoint - Dongyangguang Pharmaceutical is on the verge of officially listing on the Hong Kong Stock Exchange after successfully passing the necessary shareholder votes for privatization and merger with its subsidiary Dongyangguang Changjiang Pharmaceutical [1][2]. Group 1: Listing Process - Dongyangguang Pharmaceutical announced its application for listing on June 29, and the final step involves the approval of the privatization and merger proposal, which received over 99% support from shareholders on July 21 [1][2]. - The company will commence trading on the Hong Kong Stock Exchange on August 7, 2023 [2]. Group 2: Merger and Share Exchange - The listing will occur through a unique method of "absorption merger + introduction," marking a first in the Hong Kong market [3]. - The share exchange ratio is set at 0.263614 shares of Dongyangguang Pharmaceutical for each share of Dongyangguang Changjiang Pharmaceutical, with the theoretical value of Dongyangguang Pharmaceutical's H-shares estimated between 67.04 HKD and 81.44 HKD by the end of 2024 [4]. Group 3: Special Dividend and Shareholder Benefits - Shareholders of Dongyangguang Changjiang Pharmaceutical will receive a special dividend of 1.50 HKD per share post-merger, with approximately 4.28 billion H-shares eligible for this dividend [4][6]. - The potential premium for minority shareholders, considering the privatization and special dividend, could exceed 40% since the stock price on June 27 was 14.90 HKD, while the estimated value during privatization is around 19.36 HKD [4][6]. Group 4: Growth Potential and Innovation - Dongyangguang Pharmaceutical has seen a stock price increase of over 70% year-to-date, indicating strong market performance [6]. - The company has developed a comprehensive R&D platform over 20 years, with 150 drugs available globally and over 100 in development, including 49 first-class innovative drugs with significant commercial potential [6][7]. - Notable drugs include Clifofitinib, with a peak sales potential of 1 billion USD, and another drug, Ifenidone, which shows promise in treating various conditions [7].